Alonso-Ojembarrena I. et al. 2025. A phase 1b randomized, multicenter, dose determination trial of zelpultide alfa (recombinant human surfactant protein D) in preterm neonates at high risk of developing bronchopulmonary dysplasia. Frontiers in Pediatrics. Volume 13.